Analysis of Oxoglaucine in the Treatment of Breast Cancer Based on Network Pharmacology and Bioinformatics

To explore the potential molecular mechanism of Oxoglaucine(OG) in the treatment of Breast Cancer(BC) based on network pharmacology and bioinformatics. TCMSP and SwissTargetPrediction databases search for OG Related targets, and GeneCards database finds all BC-related targets. Take the intersection of OG and BC as all potential targets that inhibit BC. All potential targets are topologically analyzed by Cytoscape 3.7.1 software, and finally the core target is obtained. The start analysisi function in the DAVID database performs bioinformatics analysis on all core targets, and further visualizes them with the help of R language tools. As a result, 104 potential targets were obtained, of which SRC, PIK3CA, EGFR, MTOR, ESR1, MAPK1, PTGS2, AR, and NOS3 were the main core targets. OG inhibits the occurrence of BC through Pathways in cancer, PI3K-Akt signaling pathway, Proteoglycans in cancer, ErbB signaling pathway, HIF-1 signaling pathway related pathways, mainly involving signal transduction, protein phosphorylation, negative regulation of apoptotic process, positive regulation of transcription from RNA polymerase II promoter, phosphatidylinositol-mediated signaling biological processes. This study initially reveals the molecular mechanism of OG inhibiting BC, which provides a reference for further research.